CDK12 and prostate carcinoma: Indeed, our study has demonstrated that IACS‐010759, a less toxic ETC inhibitor, has shown promising therapeutic effects on CRPC, especially CDK12‐deficient CRPC cells, in vitro and in vivo, suggesting an efficient therapeutic alternative for CDK12 mutated prostate cancer patients.